VRX : Analysis & Opinions

  1. After A Sharp Pullback, Is Allergan Pretty Enough?

    July 31, 2013
    Down on fears about generics and the pipeline, the Street may be underestimating Allergan
  2. Abbott Adds Two Promising Products

    July 15, 2013
    Abbott makes two solid growth acquisitions that should address large markets.
  3. Glaxo Seeks Tafinlar-Mekinist Approval - Analyst Blog

    July 10, 2013
    GlaxoSmithKline announced that it has submitted supplemental New Drug Applications to the US Food and Drug Administration ...
  4. Roche Seeks Label Expansion for Test - Analyst Blog

    July 9, 2013
    Roche recently announced that it has submitted a Premarket Approval (PMA) supplement to the FDA for its cobas Human Papillomavirus ...
  5. Santarus Achieves New 52-Week High - Analyst Blog

    July 9, 2013
    Share price of Santarus reached a new 52-week high on Jul 8, 2013.
  6. Data from Hyperion's UCD Drugs - Analyst Blog

    June 24, 2013
    The Journal of Clinical Pharmacology reported data from Hyperion's studies.
  7. A Good Deal For Actavis, But Warner Chilcott Goes A Little Cheap

    May 21, 2013
    Actavis gets a very useful asset, while Warner Chilcott shareholders get a decent exit.
  8. Adasuve Deal Is Very Good For Alexza, But What About Teva?

    May 9, 2013
    Teva's partnership with Alexza looks like an expensive gamble.
  9. Dr. Reddy's Misses on Both Counts - Analyst Blog

    February 15, 2013
    Dr. Reddy's Laboratories (RDY) reported third quarter fiscal 2013 earnings per American Depositary Share (ADS) of 40 cents, ...
  10. Sanofi Shows Interest in Regeneron - Analyst Blog

    February 12, 2013
    Regeneron Pharmaceuticals, Inc. (REGN) recently announced that it has received a notification under the Hart-Scott-Rodino ...
  11. Warner Chilcott Provides 2013 View - Analyst Blog

    February 11, 2013
    Warner Chilcott (WCRX) recently revealed its financial guidance for 2013. The company expects to earn $3.20-$3.30 per share ...
  12. FDA Nod for Warner Chilcott Drug - Analyst Blog

    February 8, 2013
    Recently, Warner Chilcott plc (WCRX) received encouraging news when the US Food and Drug Administration (FDA) approved its ...
  13. Data on Auxilium's Xiaflex - Analyst Blog

    February 7, 2013
    Auxilium Pharmaceuticals, Inc. (AUXL) recently announced that data from the pivotal phase III trials, IMPRESS (The Investigation ...
  14. Elan Beats on Sales, Loses Tysabri - Analyst Blog

    February 7, 2013
    Elan Corporation (ELN) reported earnings of 15 cents per share for the fourth quarter of 2012 compared to the year-ago loss ...
  15. Glaxo Bottom Line Misses Again - Analyst Blog

    February 7, 2013
    GlaxoSmithKline (GSK) reported fourth quarter earnings of 57 cents per ADS, missing the Zacks Consensus Estimate of 96 cents ...
  16. Pipeline Progess at ArQule - Analyst Blog

    February 6, 2013
    ArQule, Inc. (ARQL) and partner Daiichi Sankyo recently announced that former has enrolled the first patient for the phase ...
  17. Good News for UCB - Analyst Blog

    February 6, 2013
    Good news flowed in at UCB (UCBJF) from Europe when the European Union (EU) approved Vimpat (lacosamide) as a single loading ...
  18. Elan to Sell Remaining ALKS Stake - Analyst Blog

    February 4, 2013
    Elan Corporation plc (ELN) recently decided to sell its remaining 7.8 million ordinary shares in Alkermes plc (ALKS) pursuant ...
  19. Valeant Closes Natur Acquisition - Analyst Blog

    February 4, 2013
    Valeant Pharmaceuticals International, Inc. (VRX) recently closed the acquisition of Russia-based Natur Produkt International, ...
  20. Pipeline Progress at Endocyte - Analyst Blog

    January 31, 2013
    Endocyte Inc. (ECYT) recently announced that its oncology candidate, EC0652, achieved key objectives in a phase 0 study. ...
  21. Data on Anacor Candidate - Analyst Blog

    January 30, 2013
    Anacor Pharmaceuticals, Inc. (ANAC) recently announced positive preliminary results on tavaborole (AN2690) from Study 301. ...
  22. Santarus Files Suit against Mylan - Analyst Blog

    January 30, 2013
    Santarus, Inc. (SNTS) recently filed a patent infringement lawsuit against Mylan, Inc. (MYL) which is looking to launch a ...
  23. Endo Inks Deal with Indian Company - Analyst Blog

    January 29, 2013
    In a bid to establish its presence in the highly sought after Indian market, US based Endo Health Solutions Inc. (ENDP) recently ...
  24. Positive Data on Spectrum Candidate - Analyst Blog

    January 29, 2013
    Spectrum Pharmaceuticals (SPPI) recently announced safety findings from the phase II BELIEF study on belinostat. Spectrum ...
  25. Gilead's HIV Candidate Advances - Analyst Blog

    January 25, 2013
    Gilead Sciences Inc. (GILD) recently initiated the first of two phase III studies on tenofovir alafenamide (TAF). The study ...
  26. Good news for Celgene - Analyst Blog

    January 25, 2013
    Celgene Corporation (CELG) recently announced that its oncology drug, Abraxane, has performed well in a phase III study (MPACT: ...
  27. Sales Rise at Celgene - Analyst Blog

    January 24, 2013
    Celgene Corporation's (CELG) fourth quarter 2012 earnings (excluding special items but including stock-based compensation ...
  28. In Line 4Q for Cubist Pharma - Analyst Blog

    January 24, 2013
    Cubist Pharmaceuticals Inc.'s (CBST) fourth quarter 2012 earnings (excluding special items) of 48 cents per share were in ...
  29. EU Nod for Novo Nordisk Drugs - Analyst Blog

    January 23, 2013
    Novo Nordisk (NVO) recently announced that it has received approval in the EU (covering all 27 states) for its diabetes treatments, ...
  30. Positive CHMP Opinions for Novartis - Analyst Blog

    January 23, 2013
    Novartis' (NVS) global eye care division, Alcon, recently received a positive opinion from the Committee for Medicinal Products ...
  31. CRL for Impax' Rytary - Analyst Blog

    January 23, 2013
    Impax Laboratories, Inc. (IPXL) received a major setback recently with the US Food and Drug Administration (FDA) issuing ...
  32. Patent Extension at Spectrum Pharma - Analyst Blog

    January 22, 2013
    The US Patent and Trademark Office (USPTO) recently extended the patent covering Spectrum Pharmaceuticals' (SPPI) Fusilev ...
  33. Canada Approves Forest's Bystolic - Analyst Blog

    January 22, 2013
    Forest Laboratories, Inc. (FRX) recently announced the Canadian approval of its hypertension treatment, Bystolic (nebivolol). ...
  34. Questcor Acquires BioVectra - Analyst Blog

    January 22, 2013
    Questcor Pharmaceuticals Inc. (QCOR) recently announced that it has completed the  acquisition of BioVectera Inc. for an ...
  35. Pipeline Advances at Exelixis - Analyst Blog

    January 18, 2013
    Exelixis, Inc. (EXEL) recently announced that it has received a notice from its partner, Roche Holding (RHHBY), regarding ...
  36. Onyx to Raise Funds - Analyst Blog

    January 18, 2013
    Onyx Pharmaceuticals, Inc. (ONXX) recently announced its intention to raise funds through the issuance of 4.4 million shares. ...
  37. Astellas' sNDA for Tarceva Accepted - Analyst Blog

    January 17, 2013
    Astellas Pharmaceuticals Inc. (ALPMY) recently announced that the US Food and Drug Administration (FDA) has accepted its ...
  38. Loss Widens at IRWD on Higher Costs - Analyst Blog

    January 16, 2013
    Ironwood Pharmaceuticals, Inc.'s (IRWD) fourth-quarter 2012 loss of 41 cents per share compared unfavorably with the year-ago ...
  39. Isis Pharma Updates on its Pipeline - Analyst Blog

    January 11, 2013
    Isis Pharmaceuticals, Inc. (ISIS) recently provided an update on its pipeline. Isis Pharma boasts of a robust pipeline. The ...
  40. Infinity Provides Pipeline Update - Analyst Blog

    January 11, 2013
    Infinity Pharmaceuticals Inc. (INFI) recently provided an update on its pipeline and issued its guidance for 2013. The company ...
  41. Sanofi Updates on Pipeline - Analyst Blog

    January 10, 2013
    Sanofi (SNY) recently provided an update on its pipeline. Sanofi boasts of a robust pipeline with 65 new molecular entities ...
  42. Alkermes Maintains Fiscal 2013 View - Analyst Blog

    January 9, 2013
    Alkermes plc (ALKS) recently reaffirmed its view for fiscal 2013 (ending March 31, 2013). The company continues to expect ...
  43. Forest Settles with Glenmark - Analyst Blog

    January 9, 2013
    Forest Laboratories, Inc. (FRX) recently entered into a settlement agreement with Glenmark Pharmaceuticals Ltd., relating ...
  44. Cubist Reports Impressive 4Q Sales - Analyst Blog

    January 8, 2013
    Cubist Pharmaceuticals Inc.'s (CBST) unaudited net revenues for the fourth quarter of 2012 climbed 16% year over year to ...
  45. Ironwood Winds Up Debt Offering - Analyst Blog

    January 7, 2013
    Entrepreneurial pharmaceutical company, Ironwood Pharmaceuticals, Inc. (IRWD) recently announced that it has completed the ...
  46. Impax Launches Opana ER Generic - Analyst Blog

    January 7, 2013
    Global Pharmaceuticals, the generic division of Impax Laboratories, Inc. (IPXL), a specialty pharmaceutical company, recently ...
  47. FDA Approval for Salix Drug - Analyst Blog

    January 7, 2013
    Salix Pharmaceuticals, Ltd. (SLXP) recently said that the FDA has approved the company's anti-diarrhea drug for HIV/AIDS ...
  48. Patent Challenge for Auxilium Pharma - Analyst Blog

    January 7, 2013
    Auxilium Pharmaceuticals, Inc. (AUXL) and Xstelos Holdings, Inc. (XTLS) recently received a notice from Upsher-Smith Laboratories, ...
  49. Ironwood Pharma Upped to Strong Buy - Analyst Blog

    January 3, 2013
    On January 2, 2013, Zacks Investment Research upgraded Ironwood Pharmaceuticals, Inc.'s (IRWD) to a Zacks #1 Rank (Strong ...
  50. Mylan Launches Another Generic - Analyst Blog

    January 2, 2013
    Mylan Inc.(MYL) recently announced that it has launched its generic version of Pfizer's (PFE) Dilantin Chewable Tablets (phenytoin ...
  51. Watson Files Velcade ANDA - Analyst Blog

    January 2, 2013
    Watson Pharmaceuticals, Inc. (WPI) recently announced that it is seeking FDA approval for its generic version of Millennium ...
  52. UTHR Reiterated at Neutral - Analyst Blog

    December 31, 2012
    We recently reiterated a Neutral recommendation on United Therapeutics (UTHR). While the company reported strong third-quarter ...
  53. Standard Review for Auxilium's Drug - Analyst Blog

    December 28, 2012
    Auxilium Pharmaceuticals, Inc. (AUXL) recently announced that the FDA has accepted its supplemental Biologics License Application ...
  54. Elan Hives Off Prothena - Analyst Blog

    December 27, 2012
    Elan Corporation, plc (ELN), a neuroscience-based biotechnology company, recently completed the separation of a significant ...
  55. Glaxo's Influenza Vaccine Approved - Analyst Blog

    December 24, 2012
    GlaxoSmithKline (GSK) recently announced that it has received US Food and Drug Administration (FDA) approval for its influenza ...
  56. McKesson and More Big Movers in Healthcare on December 5, 2012

    December 5, 2012
    The Nasdaq has declined 1%, the S&P 500 is trading down 0.1% and the Dow has risen 0.2% after the morning's trading. The ...
  57. Positive Data on CYTK's Tirasemtiv - Analyst Blog

    November 27, 2012
    Cytokinetics Inc. (CYTK) recently announced positive results on tirasemtiv from the phase IIa "Evidence of Effect" study ...
  58. Valeant a Step Closer to Medicis - Analyst Blog

    November 20, 2012
    Valeant Pharmaceuticals International, Inc. (VRX) is a step closer to acquiring Medicis Pharmaceutical Corp. (MRX) with the ...
  59. Allergan to Buy SkinMedica - Analyst Blog

    November 19, 2012
    Allergan, Inc. (AGN) recently announced that it has entered into an agreement with a privately held company, SkinMedica, ...
  60. Valeant Pharmaceuticals Int and More Big Movers in Healthcare ...

    October 11, 2012
    The morning has been good for the market. The Nasdaq has risen 0.3%; the S&P 500 is up 0.6%; and the Dow has climbed 0.3%. ...
  61. Gilead and Other Big Movers In Healthcare on October 1, 2012

    October 1, 2012
    It's been a good morning for the market. The Nasdaq has climbed 0.6%; the S&P 500 has increased 0.8%; and the Dow is up 1.1%. ...
  62. Valeant Buys QLT's Visudyne - Analyst Blog

    September 26, 2012
    Valeant Pharmaceuticals International, Inc. (VRX) recently announced that it has acquired QLT Inc.'s (QLTI) Visudyne. To ...
  63. Westpac Banking Corporation and More Big Movers on the NYSE on ...

    September 4, 2012
    It's been a bad day for the market so far this morning. The Nasdaq has declined 0.8%; the S&P 500 is down 0.5%; and the Dow ...
  64. Valeant Pharmaceuticals Int and More Big Movers in Healthcare ...

    September 4, 2012
    The market is currently down, with the Nasdaq slipping 0.8%, the S&P 500 down 0.6% and the Dow declining 0.8%. The healthcare ...
  65. Big Movers on the Healthcare Sector Today, Including VRX

    August 7, 2012
    The market is having a good day so far: the Nasdaq has climbed 0.8%; the S&P 500 is up 0.7%; and the Dow has risen 0.6%. ...
  66. Healthcare Sector's Biggest Movers for July 17, 2012

    July 17, 2012
    The Nasdaq has slipped 0.1%, the S&P 500 has declined 0.1% and the Dow is trading down 0.2% on a bad morning for the market. ...
  67. Today's Major Healthcare Sector Movers

    July 13, 2012
    The Nasdaq has climbed 0.5%, the S&P 500 is up 0.3% and the Dow has risen 0.5% on a good day for the market so far. The healthcare ...
  68. Biggest Healthcare Sector Movers for July 3, 2012

    July 3, 2012
    The market is doing well so far today. The Nasdaq has moved up 0.7%; the S&P 500 is up 0.7%; and the Dow has risen 0.6%. ...
  69. 4 Stocks Sitting On Support

    May 25, 2012
    Here are four stocks that are sitting on important support and are high reward-to-risk buy candidates.
  70. Obagi Puts Its Problems Behind It

    May 25, 2012
    A year ago, Obagi Medical Products faced some problems in Texas that presented an investment opportunity. One year later ...
  71. Stocks To Buy On A Market Sell-Off

    March 8, 2012
    A market pullback will create a buying opportuntiy for some of the top performing stocks.
  72. 2011 In Review - Pharmaceuticals

    December 29, 2011
    2011 was a surprisingly healthy year for drug stocks.
  73. Canada Is Key For A Strong Portfolio

    November 10, 2011
    With the majority of the developed world still facing problems, Canada is beacon of growth.
  74. Medicis May Not Stay Independent

    November 10, 2011
    Medicis is well-run, but arguably too risky to stay independent.
  75. January's Healthcare Winners

    February 4, 2011
    Check out January's best Performing Healthcare Stocks.
  76. Small Caps For Big Cures (VRTX, VRX, MLNM)

    July 27, 2007
    These three companies are on the cutting edge, but can they carve out big returns for investors?
Investing News
  1. 3 Dumb Ways to Borrow Money

    Money — everyone needs it, but not everyone has it. Many people who find themselves in a ...
  2. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  3. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  4. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  5. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
  6. What Is Worse Than Being At Risk?

    You may have heard the old adage: “What is worse than being lost? Not knowing you are lost.” ...
Trading Center